Brought to you by 
Rovi gets commercial rights to Orexigen's Mysimba in Spain
31 Aug 2016
Executive Summary
Orexigen Therapeutics Inc. licensed Laboratorios Farmaceuticos Rovi SA rights to commercialize its obesity drug Mysimba (naltrexone HCl/bupropion HCl prolonged release) tablets in Spain.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rovi gets commercial rights to Orexigen's Mysimba in Spain
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice